Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals reported strong financial performance for fiscal year 2025, ending December 31, 2025. The company generated $12.00 billion in product revenues, net, with income from operations of $4.17 billion and net income of $3.95 billion. This translated to earnings per share of $15.00 (both basic and diluted). The company maintained robust cash generation, with net cash provided by operating activities of $3.63 billion. Vertex's balance sheet remained strong with total assets of $25.64 billion, including $5.08 billion in cash and cash equivalents, and shareholders' equity of $18.67 billion. The company continued significant investment in research and development ($3.91 billion) while returning capital to shareholders through $2.02 billion in common stock repurchases. No prior period figures were provided for year-over-year comparisons.

Key Takeaways